ATE45090T1 - Pharmazeutische zusammensetzung in oralen darreichungsformen. - Google Patents

Pharmazeutische zusammensetzung in oralen darreichungsformen.

Info

Publication number
ATE45090T1
ATE45090T1 AT83307861T AT83307861T ATE45090T1 AT E45090 T1 ATE45090 T1 AT E45090T1 AT 83307861 T AT83307861 T AT 83307861T AT 83307861 T AT83307861 T AT 83307861T AT E45090 T1 ATE45090 T1 AT E45090T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
dosage form
oral dosage
microdoses
phenoxypyridine
Prior art date
Application number
AT83307861T
Other languages
English (en)
Inventor
Bruno Paul Henry Poschel
Donald Eugene Butler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE45090T1 publication Critical patent/ATE45090T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
  • Saccharide Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
AT83307861T 1983-01-03 1983-12-22 Pharmazeutische zusammensetzung in oralen darreichungsformen. ATE45090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/455,396 US4434169A (en) 1983-01-03 1983-01-03 Pharmaceutical compositions and methods
EP83307861A EP0116781B1 (de) 1983-01-03 1983-12-22 Pharmazeutische Zusammensetzung in oralen Darreichungsformen

Publications (1)

Publication Number Publication Date
ATE45090T1 true ATE45090T1 (de) 1989-08-15

Family

ID=23808634

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83307861T ATE45090T1 (de) 1983-01-03 1983-12-22 Pharmazeutische zusammensetzung in oralen darreichungsformen.

Country Status (9)

Country Link
US (1) US4434169A (de)
EP (1) EP0116781B1 (de)
JP (1) JPS59134723A (de)
AT (1) ATE45090T1 (de)
AU (1) AU555496B2 (de)
CA (1) CA1201656A (de)
DE (1) DE3380294D1 (de)
DK (1) DK1084A (de)
IE (1) IE56399B1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666926A (en) * 1986-02-27 1987-05-19 Warner-Lambert Company Transdermal formulations
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
US5173489A (en) * 1986-04-10 1992-12-22 The Dupont Merck Pharmaceutical Co. α,α-disubstituted aromatics and heteroaromatics as cognition enhancers
US4876259A (en) * 1987-01-05 1989-10-24 E. I. Du Pont De Nemours And Company 3,3-disubstituted indolines
US5232934A (en) * 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128555A (en) * 1976-12-17 1978-12-05 Warner-Lambert Company 3-Phenoxypyridine monosulfate and a method for its production
US4067983A (en) 1976-12-17 1978-01-10 Parke, Davis & Company Pharmaceutical compositions and methods

Also Published As

Publication number Publication date
AU555496B2 (en) 1986-09-25
CA1201656A (en) 1986-03-11
EP0116781B1 (de) 1989-08-02
IE56399B1 (en) 1991-07-17
DE3380294D1 (en) 1989-09-07
AU2257083A (en) 1984-07-05
IE832939L (en) 1984-07-03
DK1084A (da) 1984-07-04
US4434169A (en) 1984-02-28
JPS59134723A (ja) 1984-08-02
DK1084D0 (da) 1984-01-02
EP0116781A1 (de) 1984-08-29

Similar Documents

Publication Publication Date Title
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
LU90677I2 (fr) Esomeprazole et ses sels et d-riv-s pharmaceutiquement acceptables (nexiam)
ATE108657T1 (de) Galanthemin enthaltende pharmazeutische formulierung zur behandlung des alkoholismus.
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
ES2028917T3 (es) Un procedimiento para preparar una composicion farmaceutica inyectable estable.
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
GB1487334A (en) Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof
ATE45090T1 (de) Pharmazeutische zusammensetzung in oralen darreichungsformen.
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
ATE36531T1 (de) Verfahren zur herstellung von abgesetzten, basischen piroxicam-salzen auf einem pharmazeutisch annehmbaren traeger.
NO164958C (no) Fremgangsmaate for fremstilling av dipyridamol-preparater med ph-uavhengig, regulert frigjoering.
ATE7911T1 (de) Pharmazeutisch zulassbare salze von 4'-(9acridinylamino)methansulfon-m-anisid, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GB1246727A (en) Therapeutic hypotensive compositions comprising 5-alkylpicolinic acids
DE3265827D1 (en) Pharmaceutical composition of phosphonomicin in tablet form
IT1164217B (it) Sali di calcio di amminoacidi o di loro derivati,aventi attivita' terapeutica,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
EP0207514A3 (en) 1,4-dihydropyridine derivatives, process for preparing them, pharmaceutical composition and use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee